In naming its most innovative companies, Fast Company is "honoring leading enterprises and rising newcomers that exemplify the best in nimble business and impactful innovation." Winners this time include Amazon, Apple, Facebook, Netflix.

To produce the 2017 list, Fast Company reporters surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture. The coverage also highlights Top 10 lists in 36 sectors and geographies, from artificial intelligence to health to travel.

This section of our guiding anthem is particularly appropriate today: "Abbott has long been in the business of life. Creating more possibilities for more people through the power of health. But this business is not about reflecting on past achievements. It is about relentlessly pursuing new ones."

Thanks, Fast Company.

Abbott's Latest Breakthroughs

*FREESTYLE LIBRE & FREESTYLE LIBRE PRO: Abbott’s new sensing technology, FreeStyle Libre^TM and FreeStyle Libre^TM Pro^TM systems are in many ways the devices people with diabetes have been waiting for. Both devices are factory-calibrated and provide users and the healthcare professionals with data that enable better diabetes management. FreeStyle Libre system is currently available across 32 countries globally and is currently under review in the U.S. (pending FDA approval and not available for sale in the U.S.); FreeStyle Libre Pro system is available in India, South Africa and the U.S. TO LEARN MORE ABOUT FREESTYLE LIBRE™ PRO™, PLEASE CLICK HERE.

ALINITY: Diagnostic testing influences as much as 70 percent of healthcare decisions. Global testing volumes are rising. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs. Our solution? Alinity^TM, our harmonized family of next-generation systems across lab disciplines. Each Alinity^TM platform includes a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed healthcare environment. TO LEARN MORE ABOUT ALINITY^TM, PLEASE CLICK HERE.

ENSITE PRECISION: In arrhythmia management, advanced cardiac mapping is complex. For doctors to make sound decisions, they need precise information and they need it quickly. Our EnSite Precision^TM cardiac mapping system offers next-generation technology that allows for a high level of automation, flexibility and precision to help doctors more effectively diagnose a wide range of arrhythmias (abnormal heart rhythms). TO LEARN MORE ABOUT ENSITE PRECISION^TM, PLEASE CLICK HERE.

REALTIME ZIKA TEST: Our test to identify Zika virus ribonucleic acid (RNA) in plasma, serum and urine is now also authorized by the FDA to detect the virus in whole blood, a first from a commercial manufacturer in the U.S. Zika can be detected in whole blood for a longer period of time (up to two months) and at higher levels versus testing with serum and urine sample types. Abbott’s test could provide a more accurate diagnosis, helping people get treated and get back to better health faster. TO LEARN MORE ABOUT OUR REALTIME ZIKA TEST, PLEASE CLICK HERE.

MITRACLIP: When the mitral valve — located between your heart's two left chambers — fails to close completely, blood leaks backward inside your heart, causing a condition called mitral regurgitation, placing an extra burden on your heart and lungs. MitraClip^® can help. Clinical data from MitraClip patients show an immediate reduction of mitral regurgitation and a low average hospital length of stay of 2.9 days. Many patients report they experience significant improvement in symptoms and quality of life soon after the procedure. TO LEARN MORE ABOUT MITRACLIP, PLEASE CLICK HERE.